Slush Funds Open the Door to Beltway Corruption


By Rep. Bob Goodlatte

President Joe Biden has made eradicating government corruption a top priority: "Fighting corruption is not just good governance," he recently proclaimed. "It is self-defense. It is patriotism, and it's essential to the preservation of our democracy and our future."

But a recent rule change by his own Department of Justice would make it easier for DOJ officials to engage in dubious practices right here at home.

At issue are so-called slush-fund settlements, which allow DOJ officials to channel funds from settlements with businesses to administration-friendly advocacy groups and organizations -- undercutting Congress and skirting the law in the process.

Sadly, this kind of executive-branch corruption was rampant under the Obama administration. In that administration's last two years, DOJ officials funneled close to $1 billion in settlement money to politically favored groups entirely outside of congressional oversight. To its credit, the Trump administration halted this abusive practice.

Now, with Attorney General Merrick Garland reviving the practice, the Biden administration is not only inviting corruption in government, it's doing a disservice to victims and hard-working U.S. taxpayers, who deserve to see the money the DOJ obtains from settlements flow back to government coffers.

I should know. As chairman of the House Judiciary Committee from 2013 to 2019, I helped steer an investigation into the practice. What we uncovered was scandalous. In a settlement with a bank to settle allegations that it exacerbated the 2008 financial crisis, for example, the Obama DOJ ordered the bank to pay $25 million to left-leaning nonprofit organizations. In a similar case, the DOJ had another bank "donate" $50 million to progressive nonprofit groups in exchange for a reduced fine.

Simply put, these are federal dollars that belong to victims and the American public, not special interest groups. Federal law says as much. The Miscellaneous Receipts Act requires that any money received by the government must go to the U.S. Treasury and not to third parties.

Let's be clear here: The DOJ's mandate is to enforce the law and ensure the impartial administration of justice for all Americans. Nowhere in the Constitution or under federal law are political appointees at the nation's top law-enforcement agency imbued with the power to act as elected legislators to direct funds toward specific policy priorities.

The power to appropriate public funds rests with those elected to Congress by their constituents to represent their interests. Any monies the DOJ collects through settlement are meant to compensate victims and redress harm.

No matter who is in the White House, the DOJ's enforcement actions should support the legislative appropriations process, not undermine it. That's why putting a permanent stop to this undemocratic practice deserves bipartisan support. In fact, the bill I introduced back in 2017, the Stop Settlement Slush Funds Act, did receive bipartisan support.

Unfortunately, due to Democratic opposition, the bill never made it past the Senate. But now, Congress has a second chance to end this corrupt practice. Rep. Lance Gooden, R-Texas, and Sen. Tommy Tuberville, R-Alabama, have reintroduced the Stop Settlement Slush Funds Act this Congress. It's a common-sense bill that lawmakers -- Democrat and Republican alike -- would be wise to support.

Rep. Bob Goodlatte represented Virginia’s 6th Congressional District in the U.S. House of Representatives from 1993-2019. This piece originally ran in the Virginian-Pilot and Daily Press.



More Resources


11/22/2024
Mighty Casey Has Struck Out
Democrat Bob Casey Jr. has served in public office in this state since taking the oath of office as the state auditor general in 1997.

more info


11/22/2024
Gaetz's Implosion Shows Resistance Is Not Futile
Trump's first nominations reveal the serious fractures in his coalition - which can be used to weaken him

more info


11/22/2024
Building a Better Ground Game Critical to Trump's Victory
American Majority Action turned out low-participation voters in battleground States to help Trump and fellow Republicans to victory.

more info


11/22/2024
The Myth That Could Cost Democrats the Next Election
Progressives staying home (almost certainly) didn't cost Kamala Harris the election.

more info


11/22/2024
Jussie Smollett, the Chicago Way and MAGA


more info


11/22/2024
It's Over--Somebody Needs To Tell Bragg's Office


more info


11/22/2024
Congress Must Seize Post-Chevron Opportunity


more info


11/22/2024
Former NIH Director Francis Collins on Trump, RFK Jr.


more info


11/22/2024
How the Left Betrayed the Jews


more info


11/22/2024
I Mean, Seriously Jaguar?
In the aftermath of Trump's victory, the ad already looks like a period piece. But aside from that - I mean, seriously? says Guardian columnist Marina Hyde

more info


11/22/2024
November 22, 1963: JFK and the Futility of Blame


more info


11/22/2024
Dems Have Lost the Plot in the View of Working-Class Voters
The road back to the working class.

more info


11/22/2024
The Trump Counterrevolution Is a Return to Sanity
We are witnessing a historic counterrevolution after Trump's victory, far different from his first election in 2016.

more info


11/22/2024
Harris Disappointed Gen Z
Trump made gains among young voters in 2024, leaving Democrats wondering why.

more info


11/22/2024
Democrats Need Their Own Donald Trump
There may be five stages of grief, but there's usually just one when it comes to political defeat - pretend to soul-search, then carry on as if nothing happened.

more info



Custom Search

More Politics Articles:

Related Articles

5 Financial Pressure Points To Evaluate During COVID Times


Financial pressure is a part of life for most people, and now the COVID-19 pandemic has brought new financial pressure points or exacerbated existing ones for many individuals and families.

Why Are People Complaining About Innovative COVID Treatments?


Gilead Sciences just announced it will charge $3,120 for a full course of Remdesivir, the first new FDA-approved treatment for COVID-19. Some knee-jerk members of Congress like Lloyd Doggett (D-Tex.) immediately condemned that price tag as "outrageous." The Institute for Clinical and Economic Review, a left-leaning nonprofit that releases its own recommendations of "fair" drug prices, claimed that Gilead could afford to price Remdesivir as low as $10 per course of treatment -- the cost of the raw ingredients used to make the drug.

Proposed Healthcare Reforms Will Not Help the Latinx Community


Joe Biden is officially the Democratic presidential nominee, all thanks to his moderate reputation.

Trade Enforcement Can Accelerate America's Economic Recovery


The stock market has largely rebounded from COVID-19 and American retail sales are improving steadily. Even more encouraging is that the U.S. unemployment rate fell for the fifth consecutive month in September. Each of these gains are sure signs that the Trump administration's economic response to the coronavirus crisis is working.

Drug Price Controls: Right Objective, Wrong Solution


This month, President Trump signed an executive order to reduce Medicare spending on prescription drugs. For each medication, Medicare will pay no more than the lowest price available in other developed countries.

Keep Thanksgiving, Family and Friends Alive


Joe Biden or Donald Trump will never visit me in my home, stand beside me at the funeral home or dance at my wedding. I will not be receiving any calls from either of them to pray for me during sickness or to check on how my children are doing. I probably will never sit in a room with them to visit, laugh and tell funny stories or just to hang out over a cup of coffee. I do not personally know either one. I welcome the opportunity to visit with either of them, but doubt it will happen.

The "E" Stands for “Excellence:” Remembering Walter E. Williams


Walter E. Williams, prolific author, piercing cultural commentator, old school economist (that’s a good thing), devoted husband, loving father, and long-time friend of Grove City College has passed from this world.

How Congress Can Really Fix Surprise Billing


House and Senate leaders recently agreed on legislation to end surprise medical bills as part of a big coronavirus relief package. President Trump signed it into law at the end of December.

A Federal Rule Will Reverse Strides in Cancer Treatment


"You've got cancer." That's one of the scariest sentences in the English language.

Biden Must Restore Seniors' Access to Essential Medicines


On January 19, Medicare officials announced a new payment model that could wreak havoc on the chronically ill.

Violence In America, Don't Be Surprised


The most recent attack at the United States Capitol will most likely insure a permanent fence and additional security. The attack which resulted in the loss of life for a long serving Capitol police officer and the attacker is another senseless violent act.

Protecting the Innovation that Protects Global Health


The most far-reaching healthcare policy decision of 2021 won't be made in Congress or the White House. It will be made at the World Trade Organization, which is considering a petition to waive all patent rights on Covid-19 vaccines.

Don't Repeat Europe's Vaccine Catastrophe


For many Americans, the calamitously slow vaccine roll-out in countries like Germany, France, and Italy comes as a surprise. After all, in the early days of the pandemic, Europe's response to the crisis seemed highly competent, especially compared to the United States.

A Full Plate for the New U.S. Trade Czar


The newly confirmed U.S. trade representative, Katherine Tai, is about as qualified as a person can be for the job. Which is a good thing, because she already faces a series of challenges.

Don't Let the US Import Europe's Failed Cancer Policies


With a majority in both the House and Senate and control of the Oval Office, Democratic leaders are excited about the prospect of making significant changes. One good example of this is the House Democrats' "Lower Drug Costs Now Act."